The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,809.00
Bid: 1,808.50
Ask: 1,809.50
Change: -1.00 (-0.06%)
Spread: 1.00 (0.055%)
Open: 1,811.00
High: 1,814.50
Low: 1,806.50
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-GSK flags up pipeline as HIV drugs help it beat profit forecasts

Wed, 29th Jul 2015 13:04

* HIV sales help offset margin slide post Novartis deal

* Q2 core EPS 17.3 pence vs consensus 16.7p

* Q2 sales 5.9 billion pounds, in line with consensus

* GSK says has around 40 new drugs and vaccines in PhaseII/III

* Shares up more than 3 percent on earnings beat (Adds CEO comments on pipeline, investor reaction)

By Ben Hirschler

LONDON, July 29 (Reuters) - GlaxoSmithKline moved toreclaim its prowess as a research powerhouse on Wednesday byflagging up dozens of new drugs and vaccines in development, asdemand for new HIV medicines helped it beat quarterly profitforecasts.

Strong sales of Tivicay and Triumeq validated GSK's decisionin May to keep its HIV business, rather than spinning it off,and offset a further slide in revenue from lung drug Advair andlower group profit margins following a major business overhaul.

The drugmaker recently sold its marketed cancer drugs toNovartis and bought the Swiss group's vaccines, whileincreasing its consumer health business through a joint venture.

The $20 billion-plus asset swap was designed to ensuresustainable growth, but the strategy will take time to pay offand GSK reiterated its forecast for a high-teens percentagedecline in 2015 earnings, at constant exchange rates.

Chief Executive Andrew Witty, who reset expectations for thegroup three months ago, is now under intense pressure to delivera promised recovery from next year, following past profitdisappointments and a damaging corruption scandal in China.

Longer-term hopes hinge on the company's research pipelineand GSK said it had around 40 new drugs and vaccines in Phase IIor Phase III clinical development.

Witty told reporters he was particularly excited about a newshingles vaccine, as well as experimental drugs for chronic lungdisease and asthma, anaemia and heart disease.

R&D DAY

The company plans to showcase its line-up of noveltreatments at a research and development (R&D) event in New Yorkin November, which Witty said would be a "key moment" for thecompany. GSK last held such an R&D day in 2003.

"The company has tested the patience of long-term investorsover the past few years," said EdenTree Investment Managementanalyst Ketan Patel. "Looking forward, the focus on the R&D dayin November will be a key catalyst."

Shares in the company were up 3.5 percent by 1250 GMT,outpacing a 1.3 percent gain in the European healthcare sector.

In sterling terms, sales rose 6 percent to 5.9 billionpounds ($9.2 billion) in the three months ended June 30,reflecting the first full quarter that included productspreviously owned by Novartis.

However, core operating profit of 1.35 billion poundsgenerated earnings per share (EPS) which were down 9 percent at17.3 pence because of lower returns on Advair and the fact GSKhas swapped high-margin cancer drugs for less profitableconsumer products.

Analysts on average had forecast sales of 5.9 billion poundsand core EPS, which excludes certain items, of 16.7p, accordingto Thomson Reuters.

The company, which promised in May to pay a steady dividendfor three years, said it would pay out 19p for the quarter.

($1 = 0.6395 pounds) (Editing by Greg Mahlich and Pravin Char)

More News
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more
30 Apr 2024 12:22

Sensodyne-maker Haleon to shut UK plant, 435 jobs to go

April 30 (Reuters) - Haleon, the world's largest standalone consumer healthcare firm, will shut its UK production site which makes Sensodyne toothpastes by 2026, leading to 435 job losses, a spokesperson said on Tuesday.

Read more
25 Apr 2024 15:53

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

Read more
24 Apr 2024 14:19

UK earnings, trading statements calendar - next 7 days

Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
Gem Diamonds LtdTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Hummingbird Resources PLCTrading Statement
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
Pinewood Technologies Group PLCFull Year Results
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
Friday 26 April 
Facilities by ADF PLCFull Year Results
Kingspan Group PLCTrading Statement
Loungers PLCTrading Statement
NatWest Group PLC Q1 Results
Pearson PLCTrading Statement
Record PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Taylor Maritime Investments LtdTrading Statement
Monday 29 April 
Beazley PLCTrading Statement
Biome Technologies PLCFull Year Results
Christie Group PLCFull Year Results
Gresham House Energy Storage Fund PLCFull Year Results
Gresham Technologies PLCFull Year Results
Jadestone Energy PLCFull Year Results
Oxford BioMedica PLCFull Year Results
SpaceandPeople PLCFull Year Results
Tuesday 30 April 
Avacta Group PLCFull Year Results
Card Factory PLCFull Year Results
Capital & Regional PLCFull Year Results
Close Brothers Group PLCTrading Statement
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCHalf Year Results
Fadel Partners IncFull Year Results
Glencore PLCTrading Statement
Hargreaves Lansdown PLC Trading Statement
Howden Joinery PLCTrading Statement
HSBC Holdings PLCQ1 Results
Kelso Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Phoenix Spree Deutschland LtdFull Year Results
RBG Holdings PLCFull Year Results
Rotork PLCTrading Statement
Safestore Holdings PLCHalf Year Results
Shield Therapeutics PLCFull Year Results
St James's Place PLCTrading Statement
Strip Tinning Holdings PLCFull Year Results
Whitbread PLCFull Year Results
Wednesday 1 May 
Computacenter PLCTrading Statement
GSK PLCQ1 Results
Haleon PLCTrading Statement
HSS Hire Group PLCFull Year Results
Intelligent Ultrasound Group PLCFull Year Results
Maintel Holdings PLCFull Year Results
Next PLCTrading Statement
Smith & Nephew PLCTrading Statement
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
24 Apr 2024 09:21

GSK's endometrial cancer drug receives FDA approval

(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Jemperli, its drug aimed at treating endometrial cancer.

Read more
24 Apr 2024 09:14

GSK's Jemperli with chemotherapy accepted for priority review by FDA

(Alliance News) - GSK PLC on Wednesday said that the US Food & Drug Administration has accepted a supplemental biologics licence application for Jemperli, when used in combination with chemotherapy.

Read more
17 Apr 2024 08:46

TOP NEWS: GSK hails data on Shingles vaccine and gonorrhoea treatment

(Alliance News) - GSK PLC on Wednesday reported new test data for its shingles vaccine and for a potential new oral treatment for a form of gonorrhoea.

Read more
17 Apr 2024 07:11

GSK posts promising results from gonorrhoea treatment trial

(Sharecast News) - GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid escalating resistance to current therapies.

Read more
16 Apr 2024 09:17

GSK meningococcal vaccine accepted by US FDA for review

(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).

Read more
16 Apr 2024 08:59

GSK's latest meningitis vaccine accepted for review by US regulator

(Alliance News) - GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths of two other vaccines in its portfolio into one bacteria-fighting inoculation.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.